$5.6B acquisition of LifePoint Health approved by shareholders

A $5.6 billion merger between LifePoint Health and RCCH Healthcare Partners, which is owned by private equity firm Apollo Global Management, has been approved by LifePoint’s shareholders.

LifePoint held a special meeting of shareholders on Oct. 29 to consider the deal, which was originally announced in July. The deal was the only megadeal in the healthcare space announced during the third quarter of 2018.

The acquisition is expected to be completed before the end of the year and is subject to closing conditions, according to LifePoint. Upon closing of the transaction, LifePoint shareholders will receive $65 in cash for each share of common stock they hold.

The combined company will operate more than 80 non-urban hospitals in 30 states, regional health systems, physician practices, outpatient centers and post-acute service providers. LifePoint Health is a publicly traded healthcare services company with 71 hospitals in 22 states and more than $6 billion in revenue in 2017.

The combined entity, which will be known as LifePoint Health, will have revenues of $8 billion, with 7,000 affiliated physicians, 60,000 employees and more than 12,00 beds.

David Dill, currently LifePoint’s president and COO, will assume the role of CEO of the combined company once it closes, LifePoint announced earlier this month.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.